Oxybutynin Extended-Release Dosage & Rx Info

Oxybutynin Extended-release Generic Name & Formulations

Legal Class

General Description

Oxybutynin chloride 5mg, 10mg; ext-rel tabs.

Pharmacological Class

Antispasmodic/anticholinergic.

How Supplied

Contact supplier

Manufacturer

Various generic manufacturers

Mechanism of Action

Oxybutynin relaxes bladder smooth muscle. Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle.

Oxybutynin Extended-release Indications

Indications

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Neurologic detrusor overactivity symptoms in children.

Oxybutynin Extended-release Dosage and Administration

Adult

Swallow whole. Take with fluid. Initially 5mg or 10mg once daily; may increase weekly in 5mg increments; max 30mg/day.

Children

<6yrs: not recommended. ≥6yrs: Swallow whole. Take with fluid. Initially 5mg once daily; may increase in 5mg increments; max 20mg/day.

Oxybutynin Extended-release Contraindications

Contraindications

Urinary or gastric retention. Other severe decreased GI motility conditions. Uncontrolled narrow-angle glaucoma.

Oxybutynin Extended-release Boxed Warnings

Not Applicable

Oxybutynin Extended-release Warnings/Precautions

Warnings/Precautions

Discontinue if angioedema develops. Monitor for anticholinergic CNS effects (esp. in the first few months after initiation or dose increases); consider dose reduction or discontinuation if occur. Bladder outflow or GI obstruction. Ulcerative colitis. Intestinal atony. GERD. GI narrowing or stricture. Pre-existing dementia. Parkinson's disease. Myasthenia gravis. Decreased GI motility in those with autonomic neuropathy. Exposure to high environmental temperatures. Hepatic or renal impairment. Pregnancy. Nursing mothers.

Oxybutynin Extended-release Pharmacokinetics

Metabolism

Hepatic (CYP3A4).

Oxybutynin Extended-release Interactions

Interactions

Increased drowsiness with alcohol, other CNS depressants. Additive anticholinergic effects with other anticholinergics. May be potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin). Decreases GI motility, possibly affecting absorption of other drugs. Caution with drugs that can cause or exacerbate esophagitis (eg, bisphosphonates).

Oxybutynin Extended-release Adverse Reactions

Adverse Reactions

Dry mouth, constipation, diarrhea, somnolence, headache, dizziness, nausea, tachycardia, blurred vision, dry eyes, other anticholinergic effects.

Oxybutynin Extended-release Clinical Trials

See Literature

Oxybutynin Extended-release Note

Notes

Formerly known under the brand name Ditropan XL.

Oxybutynin Extended-release Patient Counseling